

# Review of bosentan in the management of pulmonary arterial hypertension

Eli Gabbay<sup>1</sup>  
John Fraser<sup>2</sup>  
Keith McNeil<sup>3</sup>

<sup>1</sup>Western Australian Lung Transplant Unit and Pulmonary Hypertension Service, Royal Perth Hospital, Western Australia, Australia; <sup>2</sup>Critical Care Research Group, The Prince Charles Hospital, Rode Road, Chermside, Queensland, Australia; <sup>3</sup>Transplant and Pulmonary Vascular Disease Unit, The Prince Charles Hospital, Rode Road, Chermside, Queensland, Australia

**Abstract:** The dual endothelin receptor antagonist, bosentan, is an orally active therapy, which is effective in the treatment of pulmonary arterial hypertension (PAH). This review critically appraises the evidence for the efficacy of bosentan in idiopathic and familial PAH, in PAH associated with connective tissue disease and in PAH which may develop in association with other conditions. Data from the pivotal placebo controlled studies and their open labeled extensions as well as long term survival and quality of life data is presented. Data is also presented on the potential benefit of bosentan in patients with inoperable chronic thromboembolic pulmonary hypertension. The safety and tolerability of bosentan as well as drug interactions are discussed. Dosage recommendations in adults and pediatrics are presented. An algorithm is provided to guide the reader in monitoring potential increases in alanine and aspartate transaminase levels that may occur with bosentan use and the dose adjustments that are recommended as a result of any increase in the levels of these enzymes are shown. Finally, the role of bosentan as part of combination therapy in PAH is examined.

**Keywords:** bosentan, pulmonary arterial hypertension, review

## Introduction

Pulmonary arterial hypertension (PAH) is a condition characterized by dyspnea, fatigue, chest pain and syncope (Gaine and Rubin 1998; Runo and Loyd 2003; Galie 2004; Rubin 2004). PAH results from narrowing of the small arteries and arterioles resulting in elevation of pulmonary vascular resistance (PVR), which if left untreated, results in the development of right ventricular failure and death.

The pathogenesis that underlies PAH has become better understood. Central to the development of PAH is pulmonary vascular endothelial cell dysfunction. The role of endothelin as a central mediator in the development of PAH has been demonstrated and this has resulted in the development of endothelin receptor antagonists (ERAs), which have favorably impacted on symptoms, exercise capacity and prognosis for patients with PAH (Humbert, Morrell et al 2004).

Bosentan, a dual endothelin receptor antagonist, is the first ERA to be used successfully in the treatment of PAH. This article reviews the evidence for the use of bosentan in PAH including its efficacy in various types of PAH, its potential toxicity, and associated drug interactions.

## Definition and classification

Pulmonary hypertension is defined as a sustained elevation of mean pulmonary artery pressure to a level greater than 25 mmHg at rest or greater than 30 mmHg during exercise (Runo and Loyd 2003; Galie 2004; Rubin 2004).

Previously, pulmonary hypertension was defined as primary (PPH) or secondary (Gaine and Rubin 1998). More recently, a series of World Health Organization

Correspondence: Eli Gabbay  
Western Australia Lung Transplant Unit and Pulmonary Hypertension Service, Royal Perth Hospital, GPO Box X2213, Perth, Western Australia, 6001  
Tel + 618 9224 3853  
Fax +618 9224 3866  
Email Eli.Gabbay@health.wa.gov.au

sponsored expert conferences suggested replacing this simplistic categorization with a new classification (Table 1) (Simonneau et al 2004). This classification distinguishes pulmonary hypertension via a combination of the underlying mechanisms and etiology, and is more useful when considering the natural history, prognosis and potential therapies of this disorder. Most of the therapies that have been utilized in pulmonary hypertension have been found to be efficacious in group 1 (PAH) of this classification. In this classification, the term primary pulmonary hypertension has been replaced by the terms idiopathic pulmonary arterial hypertension and familial pulmonary arterial hypertension. Patients with PAH (Group 1) have evidence of sustained elevation in pulmonary pressure and additionally have a normal pulmonary artery wedge pressure <15 mmHg. Additionally, this group excludes patients where the underlying cause of the elevated pulmonary pressure is felt to be related to hypoxemic lung disease (Group 3), thromboembolic disease of the pulmonary vasculature (Group 4), or miscellaneous other causes (Group 5).

Pulmonary hypertension in clinical practice most commonly arises as a result of left heart disease (Group 2). It is important to note that the therapies discussed in this article

have not been found to be helpful (and are potentially deleterious) in this group of patients. Pulmonary hypertension may arise from chronic thromboembolic disease (CTEPH) (Moser et al 1990). This condition needs to be excluded when a diagnosis of PAH is being considered because treatment of this condition is predominantly surgical, although medical therapy may be effective in selected cases (Bresser et al 2004; Bonderman et al 2005; Hoeper et al 2005; Rubin et al 2006).

Pulmonary hypertension can occur in association with lung disease and/or hypoxemia. In these conditions treatment is directed to the underlying cause and correction of the hypoxemia although it may yet transpire that the PAH specific therapies discussed below may have a role in these patients (Jones et al 1989; Strange 2005).

## Pathogenesis and rationale for PAH therapies

A detailed discussion of the pathogenesis of PAH is beyond the scope of this article and readers are referred elsewhere (Voelkel et al 1997; Humbert, Morrell et al 2004). In summary, established PAH is characterized by constriction of the pulmonary arterioles resulting predominantly from vascular

**Table 1** WHO Classification of pulmonary hypertension (abridged) (Humbert, Morrell et al 2004)

### Group 1: Pulmonary arterial hypertension (PAH)

- Idiopathic (IPAH)
- Familial (FPAH)
- Associated with (APAH)
  - Collagen vascular disease (connective tissue disease)
  - Congenital systemic-to-pulmonary shunts (Eisenmenger syndrome)
  - Portal hypertension (Portopulmonary hypertension)
  - HIV infection
  - Drugs and Toxins
  - Other (including thyroid disorders, hemoglobinopathies, myeloproliferative disorders, splenectomy)
- Associated with significant venous or capillary involvement
  - Pulmonary veno-occlusive disease (PVOD)
  - Pulmonary capillary hemangiomatosis (PCH)
- Persistent pulmonary hypertension of the newborn

### Group 2: Pulmonary hypertension with left heart disease

- Left-sided atrial or ventricular heart disease
- Left-sided valvular heart disease

### Group 3: Pulmonary hypertension associated with lung disease and/or hypoxemia

- Sleep Disordered Breathing
- Interstitial Lung Disease
- COPD
- Chronic exposure to high altitude

### Group 4: Chronic thromboembolic pulmonary hypertension (CTEPH)

### Group 5: Miscellaneous

- Sarcoidosis
- Histiocytosis X

remodeling, with variable contributions from vasoconstriction and thrombosis. The role of the characteristic plexiform lesions in the pathogenesis and natural history of PAH is unclear.

Within the pulmonary arterioles, the main cellular changes involve the endothelium, platelets, smooth muscle cells and adventitial fibroblast. PAH arises from a complex interplay of molecular and genetic abnormalities resulting in these cellular changes (Humbert, Morrell et al 2004).

Endothelial cell injury and dysfunction is central to the development of the abnormalities seen in PAH, and this results in an imbalance in vaso-active mediators normally produced by the endothelium. Central to the development of PAH is reduced production of prostacyclin (PGI<sub>2</sub>), nitric oxide (NO) and vasoactive intestinal peptide (VIP), with upregulation of endothelin 1 (ET-1) (Humbert, Sitbon et al 2004). The currently available PAH therapies act at least in part, by helping redress this imbalance.

## Epidemiology and genetics

The incidence and prevalence of idiopathic pulmonary arterial hypertension is uncertain. The reported incidence appears to lie somewhere between 1 and 2 per million per year (Rubin 2004) to as high as between 2.5 and 4 per million per year (Stewart et al 2007). The incidence of PAH is higher in certain families. Familial PAH accounts for between 6%–10% (Newman et al 2001) of all patients.

Underlying the development of both familial and idiopathic PAH are genetic mutations in the TGF-beta receptor families. Mutations in the gene encoding bone morphogenetic protein receptor type 2 (BMPR - II) have been identified as being important in the development of PAH in most, if not all, patients with familial PAH (Lane et al 2000) as well as between 10% and 26% of patients with idiopathic PAH (Lane et al 2000).

PAH can also be seen in association with a variety of other conditions as described in Group 1 of the World Health Organization Venice classification (Table 1). These associated conditions include connective tissue disease and especially systemic sclerosis (particularly limited cutaneous scleroderma), portopulmonary hypertension, certain drugs and toxins, HIV infection, and congenital systemic to pulmonary shunts (Eisenmenger syndrome). It has become increasingly recognized that other conditions, especially certain hematologic, genetic and metabolic disorders are also associated with the development of PAH. The role of genetic mutations in these associated causes of PAH remain unclear.

Nonetheless, it is evident that one genetic mutation and/or one environmental stimulus cannot explain all forms of

PAH. Other candidate genes that are considered relevant to the development of PAH include genes encoding regulating factors in the serotonin pathway as well as other genes related to TGF-beta signaling pathways.

What is clear is that PAH arises from an interplay between multiple genetic and environmental factors. This multi-hit hypothesis (Farber and Loscalzo 2004) suggests that the development of PAH requires primary genetic abnormalities, which when influenced by environmental stimuli lead to the development of clinically evident PAH.

## Role of endothelin

One of the most important abnormalities in PAH is an over expression of endothelin-1 (ET-1). This results in abnormally high concentrations in pulmonary arteries (Giaid et al 1993) and an increase in circulating ET-1 (Humbert, Morrell et al 2004; Rubin 2004). Upregulation of ET-1 contributes to smooth muscle vasoconstriction and hypertrophy as well as fibrosis and inflammation. This is important in both the development of pulmonary arteriolar constriction and the secondary right ventricular hypertrophy which is seen in PAH. Circulating and pulmonary ET-1 concentrations are strongly correlated with disease severity and prognosis in PAH (Giaid et al 1993; Galie et al 1996; Humbert, Morrell et al 2004; Rubin 2004).

Synthesis of ET-1 arises from the cleavage of a 212 residue precursor peptide known as pre pro ET-1, first to the 38 amino acid big ET-1, then by endothelin converting enzyme to the active 21 amino acid isoform.

ET-1 acts upon two receptor sub types, ET<sub>A</sub> and ET<sub>B</sub>. These receptors mediate the physiological and pathological effects of ET-1. ET<sub>A</sub> receptors are found predominantly on vascular smooth muscle cells and induce vasoconstriction. ET<sub>B</sub> receptors also appear on vascular smooth muscle cells where they stimulate both vasoconstriction and smooth muscle hyperplasia (Clozel et al 1992; Neylon et al 1994). However, ET<sub>B</sub> receptors predominate on endothelial cells where they stimulate the release of vasodilating and anti-proliferative mediators such as prostacyclin (Levin 1995). Under physiological conditions the predominant effect of the ET<sub>B</sub> receptor is a vasodilatory response (Levin 1995). However, in a pathological state such as PAH, the predominant effect of stimulation of the ET<sub>B</sub> receptors is that of vasoconstriction and vascular smooth muscle proliferation (Benigni and Ramuzzi 1999). Both ET<sub>A</sub> and ET<sub>B</sub> receptors appear to be important in mediating the response to endothelin of fibrosis, vasoconstriction and inflammation (Katwa et al 1993; Filep et al 1995). Furthermore, stimulation of both ET<sub>A</sub> and

ET<sub>B</sub> receptors by endothelin is important in the myocardial hypertrophy and myocardial fibrosis which is seen in PAH (Levin 1995).

Given the central role of upregulated ET-1 in the pathogenesis of PAH, the role of ET receptor antagonists in PAH received greater attention. The best studied of these endothelin receptor antagonists is bosentan, a dual ET<sub>A</sub> and ET<sub>B</sub> receptor antagonist. More recently, the ET<sub>A</sub> selective receptor antagonists sitaxsentan and ambrisentan have undergone clinical trials in PAH. The relative benefits of dual ET<sub>A</sub> and ET<sub>B</sub> receptor antagonism versus selective ET<sub>A</sub> receptor antagonism remains unclear. Preliminary data suggests that ET<sub>A</sub> selective antagonism may be as effective, at least in idiopathic PAH and scleroderma associated PAH as dual ET<sub>A</sub> and ET<sub>B</sub> receptor antagonism (Benedict 2007).

## Treatment of PAH

### Conventional therapy for PAH

General measures including management of underlying or contributing factors, avoidance of pregnancy, early treatment of intercurrent respiratory infections with antibiotics and the use of influenza and anti-pneumococcal vaccines are recommended (Galie 2004; Rubin 2004). Oxygen is given for hypoxemia and diuretics are efficacious in the treatment of congestive heart failure. Digoxin may be of benefit, especially if the patient is in atrial fibrillation. Non steroidal anti inflammatory medications and decongestant tablets containing pseudoephedrine are usually avoided (Galie 2004; Rubin 2004).

Anticoagulation with warfarin is used in most of the patients based on single center, retrospective studies (Fuster et al 1984; Rich et al 1992).

Improved survival has been seen with high dose calcium channel blockers in the 5%–10% of patients with idiopathic PAH who have demonstrated acute reactivity in response to pulmonary vasodilator testing. The use of high dose calcium channel blockers is indicated in patients with WHO functional class II to III who display acute reactivity and remain stable (Galie et al 2004).

### Specific PAH therapies

In recent years, the development of specific PAH therapies has increased the options available to the clinician managing a patient with PAH. There are four main classes acting upon three main intracellular pathways (Table 2, Figure 1) (Humbert, Sitbon et al 2004).

These currently available specific PAH therapies aim to redress the imbalance in mediators which occur as a result

of endothelial cell dysfunction. This imbalance consisting of reduced production of prostacyclin and nitric oxide and upregulation of ET-1 resulting in the abnormal proliferation and contraction of pulmonary smooth muscle cells via three pathways, all of which are potential targets for therapy (Figure 1 and Table 2) (Humbert, Sitbon et al 2004).

Intravenous epoprostenol (prostacyclin) was the first effective agent to be used for the treatment of PAH, and to date remains the only agent that has been shown to improve survival in a randomized controlled trial of patients with (idiopathic) PAH (Barst et al 1996). Intravenous epoprostenol is limited by the need for a continuous intravenous infusion pump with the potential problem of line sepsis. Further, it is limited by side effects arising from the direct effect of the medication including jaw pain, headaches, flushing and gastrointestinal disturbance.

The prostacyclin analogues treprostinil (which can be given either intravenously or by subcutaneous infusion) and iloprost (which can be given either through the inhaled route or intravenously), have also been shown to improve exercise capacity and WHO functional class (Olschewski et al 2002; Simonneau et al 2002). The current recommendation is that where there are alternatives, the oral prostacyclin analogue, beraprost, should be avoided as it is ineffective in the medium to long term (Galie 2004).

The phosphodiesterase-5 (PDE-5) inhibitor sildenafil has been associated with improvements in WHO functional class, hemodynamics and exercise capacity in a placebo controlled trial (Galie et al 2005). The authors are aware that some

**Table 2** Specific PAH therapies and method of delivery

#### Prostacyclin/prostacyclin analogues

- Epoprostenol          iv
- Treprostinil        iv, sc or inhaled
- Iloprost            iv or inhaled
- Beraprost          oral

#### Endothelin receptor antagonists

Dual ET<sub>A</sub> and ET<sub>B</sub> blockade

- Bosentan          oral

Selective ET<sub>A</sub> blockade

- Sitaxsentan        oral
- Ambrisentan      oral


#### Nitric oxide/nitric oxide donors

- Nitric Oxide inhaled
- L-Arginine        oral

#### Phosphodiesterase-5 inhibitors

- Sildenafil          oral
- Tadalafil          oral

**Abbreviations:** iv, intravenous, sc, subcutaneous.



**Figure 1** Consequences of endothelial dysfunction on pulmonary vascular smooth muscle showing potential targets for therapy. Three major pathways and associated therapeutic targets in abnormal proliferation and contraction of smooth muscle cells are shown. Dysfunctional endothelial cells have decreased production of prostacyclin and endogenous nitric oxide and increased production of endothelin-1. This imbalance of mediators along with decreased production of vasoactive intestinal peptide (VIP) results in a condition favouring vasoconstriction and proliferation of pulmonary artery smooth muscle cells. In addition to their actions on smooth muscle, these mediators have other properties including antiplatelet effects of nitric oxide and prostacyclin and profibrotic and proinflammatory effects of endothelin. Plus signs denote an increase in intracellular concentration; minus signs reflect blockage of a receptor, inhibition of an enzyme or a decrease in the intracellular concentration. (Modified and published with permission from Humbert, Sitbon et al (2004)).

**Abbreviations:** cGMP cyclic guanosine monophosphate; cAMP, cyclic adenosine monophosphate.

clinicians have used the PDE-5 inhibitor, tadalafil, in selected patients due to availability and cost constraints but as yet there is no published data of its long term effectiveness.

Inhaled nitric oxide is efficacious in lowering pulmonary pressures and improving hemodynamics in ventilated patients (Zapol et al 1994) but is generally limited to the intensive care unit setting and generally necessitates positive pressure ventilation. Prolonged nitric oxide administration can induce methaemoglobinemia and platelet dysfunction.

## Bosentan therapy in PAH

Bosentan was the first endothelin receptor antagonist approved for the use of PAH.

Clinical studies have shown that in PAH, the use of bosentan is associated with improved exercise capacity, WHO

functional class, cardiopulmonary hemodynamics, quality of life and delayed time to clinical worsening when compared to placebo. Further, long term studies have demonstrated improved survival with the use of bosentan when compared to historical controls although there is no placebo controlled data confirming a survival benefit (Table 3).

## Placebo-controlled pivotal studies and open labeled extension

In the first placebo controlled study of bosentan in PAH (Channick et al 2001) Channick and co-authors reported on 32 patients with either idiopathic PAH or scleroderma associated PAH who were randomly assigned to receive bosentan (62.5 mg taken twice daily for four weeks then 125 mg twice daily) or placebo for a minimum of 12-weeks. The primary

**Table 3** Impact of bosentan therapy in patients with idiopathic pulmonary arterial hypertension

Parameter showing improvement	Study	p value
Survival	McLaughlin	<0.01 <sup>a</sup>
Time to clinical worsening	Rubin	= 0.0015
Exercise capacity (6MWD <sup>b</sup> )	Rubin	<0.001
	Channick	= 0.021
Cardiopulmonary hemodynamics	Channick	<0.001 for CI <sup>c</sup> , PVR <sup>d</sup> and RAP <sup>e</sup>
WHO functional class	Rubin	= 0.04
Quality of Life	Keogh	<0.0001 for physical function
Echocardiographic parameters	Galie	= 0.007

**Abbreviations:** <sup>a</sup>compared to predicted survival based upon NIH registry; <sup>b</sup>6MWD, six minute walk test distance; <sup>c</sup>CI, Cardiac Index; <sup>d</sup>PVR, pulmonary vascular resistance; <sup>e</sup>RAP, mean right atrial pressure.

end point was change in exercise capacity. Secondary end points included change in cardiopulmonary hemodynamics, BORG dyspnea index, WHO functional class and withdrawal due to clinical worsening.

In patients given bosentan, the distance walked in 6 minutes improved by 70 meters after 12-weeks compared with baseline where as in those on placebo it worsened by 6 meters (treatment effect 76 m,  $p = 0.021$ ). There was also a significant improvement in cardiac index and reduction in pulmonary vascular resistance. Further, patients who received bosentan had improved WHO functional class and reduced BORG dyspnea index. Only 3 patients withdrew from the study from clinical worsening and all were within the placebo group ( $p = 0.033$ ).

In 2002, Rubin and co-authors reported the results of a much larger placebo controlled study (Rubin et al 2002). In this double blind study, 213 patients with either idiopathic PAH or PAH associated with connective tissue disease received either placebo or bosentan with an initial dose of 62.5 mg twice daily for 4-weeks followed by either of 2 doses of bosentan (125 or 250 mg twice daily) for a minimum of 12-weeks.

By week 16, the treatment effect of bosentan (improvement in 6 minute walking distance in bosentan group minus improvement in 6 minute walk distance in placebo group) was 44 meters ( $p < 0.001$ ). Bosentan also improved the WHO functional class and delayed time to clinical worsening.

85 of the 213 patients enrolled in this study were included in an echocardiographic sub study (Galie et al 2003). At baseline, patients had echocardiographic findings consistent with severe PAH. Treatment effects of

bosentan compared with placebo after 16 weeks showed improvements in the echocardiographic measures of cardiac index, right ventricular function and right ventricular size and function and reduced frequency of pericardial effusion. Further, left ventricular early diastolic filling was improved in the bosentan group suggesting reduced compression of the left ventricle by a dilated and hypertrophied right ventricle and/or better flow to pulmonary veins secondary to reduced pulmonary pressure allowing earlier and better filling characteristics.

In all three of these studies (Channick et al 2001; Rubin et al 2002; Galie et al 2003) patients were in WHO functional class III or IV at baseline.

29 of the 32 patients enrolled in the original study (Channick et al 2001) received bosentan at a dose of 125 mg twice daily in an open labeled extension for an additional year. This one year follow up study (Sitbon et al 2003) found that improvements in 6 minute walk distance that were achieved with bosentan in the original study were maintained. 41.4% of patients improved their NYHA functional class, whereas only 1 patient had a deterioration in functional class. Further, 11 patients underwent repeat right heart catheterization between 8 and 22-months after commencement of treatment with bosentan. For these patients, cardiac index and PVR was significantly improved compared to baseline. There was also a small reduction in mean pulmonary artery pressure, which did not reach statistical significance.

## Effect of bosentan on survival in idiopathic PAH

None of the placebo-controlled trials of bosentan in PAH were powered to show survival benefit. Therefore the only information available regarding survival benefit from bosentan comes from comparisons with historical controls and National Institute of Health (NIH) registry data.

In 2005, McLaughlin and colleagues (2005) reported the first long term survival data with bosentan in patients with idiopathic PAH. All patients were in WHO functional class III or IV at baseline. The authors reported on 169 patients with idiopathic PAH who received bosentan as first line therapy for their disease. After 12 and 24-months of follow up, 85% and 70% of patients, respectively remained on bosentan monotherapy. Another 7% continued bosentan while receiving additional therapies.

The Kaplan-Meier survival estimate at two years was 89% in this study compared to the predicted two years survival (based on historical cohorts) of 57%. At each six month interval, observed survival was significantly better

than predicted. Overall, patients receiving first line bosentan therapy had a 5.5% annual death rate (Figure 2).

In 2005, Sitbon and colleagues (2005) compared the survival of 139 patients with idiopathic PAH in WHO functional class III who received bosentan as first line therapy with historical records of patients who received intravenous epoprostenol as first line therapy. After correcting for differences in severity at baseline, there was no significant difference in one and two year survival between the two groups. This is particularly important because intravenous epoprostenol therapy is the only treatment that has been shown to improve survival in PAH in a prospective placebo controlled study (Barst et al 1996).

In a large single center study, Provencher and colleagues (2006) examined the survival of 103 consecutive patients with NYHA functional class III or IV idiopathic PAH who were treated first line with bosentan. Bosentan was prescribed at a dose of 62.5 mg twice daily for 4-weeks followed by 125 mg twice daily. The mean duration of follow up was  $24 \pm 15$ -months and overall survival estimates were 92, 89 and 79% at 1, 2 and 3-years respectively. The predicted survival at 1, 2 and 3-years, based on the equation derived from the NIH registry (D'Alonzo et al 1991) was 71, 61 and 51% respectively. Intravenous epoprostenol was added in 30 patients and inhaled iloprost in an additional 6 patients following a mean duration of exposure of bosentan of  $12 \pm 10$ -months. The reasons for the initiation of additional therapy included worsening of NYHA functional class on


treatment, a significant fall in 6 minute walk distance or failure of significant improvement in cardiac index.

## Bosentan in connective tissue disease associated PAH

PAH can complicate all forms of connective tissue disease. Most commonly it complicates systemic sclerosis (scleroderma) especially the limited cutaneous subtype. Depending on the criteria used, PAH can complicate up to 25% of patients with limited cutaneous scleroderma (Hoepfer 2002). However, PAH can also complicate SLE, mixed connective tissue disease and less commonly, rheumatoid arthritis (Hoepfer 2002).

Overall, the results with bosentan (or any other specific PAH therapy) have not been as impressive with scleroderma associated PAH when compared to idiopathic PAH. This most probably reflects a different pathogenesis, older age of patients and that these patients tend to present later in their disease course (Hoepfer 2002). As a result many groups are recommending that all patients with scleroderma regardless of symptomatology be screened for the presence of PAH by serial echocardiography and lung function (Black 2005).

Denton and colleagues (2006) analyzed the results of bosentan therapy for PAH related to connective tissue disease from the two placebo-controlled clinical trials and their open labeled extensions. 66 patients with connective tissue disease associated PAH, in WHO functional class III or IV were randomized to participate in the pivotal placebo



**Figure 2** Survival in adult patients with idiopathic pulmonary arterial hypertension treated with first line bosentan therapy compared to predicted survival with conventional therapy according to NIH registry. (Reproduced with permission from McLaughlin et al (2005)).

controlled studies (Channick et al 2001; Rubin et al 2002). 44 patients received bosentan and 22 patients received placebo. Baseline characteristics suggested that the group who received bosentan had more severe disease with a lower 6 minute walk distance and higher PVR at baseline. There was a treatment effect of 22 meters favoring bosentan compared with placebo (not significant) although time to clinical worsening was delayed by bosentan, suggesting slower disease progression.

64 of these original 66 patients continued in an open labeled extension. 40 of these patients remained on bosentan monotherapy, one received prostanoids in addition to bosentan and in 23 patients, bosentan was ceased. The mean duration of bosentan therapy in this group of patients was  $1.8 \pm 0.8$ -years. Survival was 85.9% at one year and 73.4% at two years and of the 40 patients on bosentan monotherapy, 25% improved in WHO functional class by end of treatment.

Williams and co-authors (2006) reviewed the data of 45 patients in a routine clinical setting with scleroderma associated PAH who received bosentan monotherapy. Survival in this group was 81% at one year and 71% at two years. This was similar to the survival reported by Girgis and colleagues (2005) who found an 87% one year and 79% two year survival for 17 patients with scleroderma associated PAH who received bosentan as first line therapy.

## Effect of bosentan on quality of life of patients with PAH

In an uncontrolled Australian study bosentan monotherapy was associated with significant improvements in quality of life, as measured by the SF-36 questionnaire, which persisted for 12-months (Keogh et al 2007). Patients with idiopathic or familial PAH as well as those with connective tissue disease were included in this study. All patients were in WHO functional class III or IV at baseline and had not had previous treatment with specific PAH therapies. Analysis of a sub group of this study showed that bosentan also improved six minute walk distance over a 12-month period and that quality of life and six minute walk distance were well correlated although improvements in quality of life appeared to be a more sensitive indicator of response to treatment than changes in six minute walk distance (Gabbay et al 2005).

## Recommendations for role of bosentan monotherapy in PAH

The data from the studies in idiopathic, familial and Scleroderma-associated PAH has led to the recommendation that bosentan monotherapy is indicated for patients in WHO

functional class III in these conditions (Galie 2004). Bosentan also appears to be effective in patients in WHO functional class IV but it remains unclear if it is a preferred first line therapy compared to intravenous epoprostenol, where there appears to be more evidence for intravenous epoprostenol therapy (Galie 2004). In patients with idiopathic or familial PAH who present in WHO class IV with evidence of right ventricular dysfunction, the authors and others recommend that intravenous epoprostenol be considered as first line therapy (Galie 2004).

In those patients who are stabilized on intravenous epoprostenol, especially at low doses, it may be possible to switch them to bosentan monotherapy although this needs to be done with a very slow reduction of epoprostenol dose and concomitant monitoring (Steiner et al 2006).

Bosentan has been shown to be effective in a placebo-controlled trial in patients in WHO functional class II (EARLY Study – Actelion press release). However, at the time of writing this study is unpublished and regulatory authorities in most countries have not approved bosentan for use in this class of patients. Therefore its use would be limited by the current prohibitive costs for most individuals in WHO class II (see discussion on cost-effectiveness and availability).

The role of bosentan as part of combination therapy in PAH is discussed later in this article.

## Bosentan in other forms of associated PAH

Most of the clinical studies of bosentan in PAH have concentrated on patients with idiopathic and familial PAH as well as those with PAH in association with connective tissue disease especially scleroderma. However, there is also evidence of the efficacy of bosentan in PAH associated with HIV infection and PAH associated with congenital heart disease as well as in the pediatric population (Table 4).

In a study on the effects of bosentan on human immunodeficiency virus associated PAH, Sitbon and colleagues (2004) described the results of bosentan therapy given for 16-weeks in 16 patients. In patients with HIV infection, the HIV-1 envelope glycoprotein 120 may stimulate the production of endothelin. Endothelin levels are significantly elevated in patients with vascular complications of HIV infection. The authors postulated that endothelin may contribute to the pathogenesis of vasculopathies associated with HIV infection, including PAH. In this open labeled uncontrolled study the authors found that 6 minute walk distance improved by 91 meters ( $p < 0.001$ ) and there were significant improvements in NYHA functional class, cardiopulmonary



**Table 4** Impact of bosentan therapy in pulmonary arterial hypertension (PAH) subgroups

PAH sub-group	Parameter showing improvement	Study
Scleroderma associated PAH	Survival <sup>a</sup>	Denton, Williams,
	time to clinical worsening	Girgis, Denton,
	6-MWD <sup>b</sup>	Denton,
	WHO functional class	Denton,
HIV associated PAH	Quality of life	Keogh
	6-MWD <sup>b</sup>	Sitbon,
	WHO functional class	Sitbon,
	Hemodynamics	Sitbon,
Eisenmenger syndrome	Quality of life	Sitbon
	6-MWD <sup>b</sup>	Galie,
	WHO functional class	Galie,
Pediatric PAH	Hemodynamics	Galie
	Survival <sup>a</sup>	Rosenzweig,
	WHO functional class	Rosenzweig,
	Hemodynamics	Barst, Rosenzweig

**Note:** <sup>a</sup>compared to historical data.

**Abbreviation:** <sup>b</sup>6-MWD, six minute walk test distance.

hemodynamics, Doppler echocardiographic variables and quality of life. During the study, no patient died and none required other therapies towards their PAH. Furthermore, bosentan did not have a negative impact on control of HIV infection, nor did its use significantly interact with anti-retroviral therapy.

Congenital heart disease characterized by the development of systemic to pulmonary shunting (eg, atrial septal defect, ventricular septal defect, patent ductus arteriosus) may lead to the development of PAH and consequent intracardiac right to left shunting (Eisenmenger syndrome). Galie and co-authors (Galie et al 2006) reported the results of a 16-week double blind placebo controlled study evaluating the effect of bosentan in Eisenmenger syndrome. 54 patients were randomized to receive either bosentan (n = 37) or placebo (n = 17). Despite theoretical concerns that vasodilator therapy may reduce systemic blood pressure more than pulmonary pressures and hence worsen right to left shunt, bosentan did not worsen oxygen saturations. The treatment effect of bosentan when compared to placebo was an increase in six minute walk distance of 53.1 m (p = 0.0079) and a significant fall in PVR and mean pulmonary artery pressure.

In an open label study, Kotlyar and co-authors (Kotlyar et al 2006) evaluated the effects of bosentan in 23 patients with Eisenmenger syndrome. There was a mean duration of follow up of 15 ± 10-months, 57% of the patients had improved by at least one functional class (p = 0.016) and mean oxygen saturation at rest increased from 81% to 84%

(p = 0.001). Overall, the six minute walk distance did not change from the baseline of 335 m.

Pulmonary hypertension may complicate chronic thromboembolic disease. Although chronic thromboembolic pulmonary hypertension (CTEPH) is a different disease to idiopathic PAH, with different underlying mechanisms, some similarities in the pathogenesis and pathology of these conditions exist. Pulmonary endarterectomy (PEA) surgery is the treatment of choice for patients with severe CTEPH and appropriate disease distribution (Jamieson et al 2003). However, a substantial proportion of patients with CTEPH are considered inoperable due to significant distal thromboembolic pathology or due to concomitant morbidity. It has been postulated that in patients with CTEPH who can not undergo PEA or in whom pulmonary hypertension persists following surgery, then specific PAH therapies may be effective.

A summary of the effects of bosentan in either inoperable CTEPH or persistent pulmonary hypertension after PEA is shown in Table 5. In summary, bosentan therapy for a treatment duration of up to three years has been associated in these open labeled studies with improvements in NYHA functional class, exercise capacity and cardiopulmonary hemodynamics (Bonderman et al 2005; Hoeper et al 2005; Hughes et al 2005, 2006). Further, an open labeled study by Musk and colleagues (2006) found that treatment with Bosentan in CTEPH was associated with improvements in exercise capacity and cardiopulmonary hemodynamics that were similar to the improvements seen in a similarly treated group of patients with idiopathic PAH and with a trend to greater improvements than those seen with scleroderma associated PAH in the same center.

A multi center randomized trial in patients with inoperable CTEPH (BENEFIT), which includes a four month bosentan/placebo controlled phase, found that bosentan was associated with reduced PVR and prolonged time to clinical worsening when compared to placebo but there was no difference in exercise capacity (as measured by 6 minute walk test) in the two groups (Jais et al 2007). The results from the open labeled extension are awaited to help determine if exercise capacity improves in the longer term and this may help to clarify the role of bosentan in CTEPH.

## Pediatrics

The data on efficacy and safety of bosentan in pediatric patients with PAH is not as extensive as that in adults. Barst and colleagues (2003) describe three different dosing regimes of bosentan in 19 pediatric patients stratified for body weight

**Table 5** Impact of bosentan therapy in chronic thromboembolic pulmonary hypertension (CTEPH)

Study	Indication	n	Treatment duration	Parameter showing improvement
Bonderman et al 2005	Inoperable CTEPH	16	6 months	NYHA functional class 6-MWD <sup>a</sup>
Hoepfer, Kramm et al 2005	Inoperable CTEPH	19	3 months	Hemodynamics 6-MWD
Hughes	Inoperable CTEPH/ Persistent PH after surgery	20	>3 months	Hemodynamics 6-MWD
Hughes	Inoperable CTEPH/ Persistent PH after surgery	47	1 year	WHO functional class Hemodynamics 6-MWD

**Abbreviation:** <sup>a</sup>6-MWD, six minute walk test distance.

and epoprostenol use. They found that the pharmacokinetics of bosentan in pediatric patients with PAH and healthy adults were similar and the treatment with bosentan resulted in hemodynamic improvement. Rosenzweig and colleagues (2005) described the use of bosentan in 86 children with either idiopathic PAH or PAH associated with congenital heart disease or connective tissue disease. Median exposure to bosentan was 14-months. In 46% of the patients, WHO functional class improved and there was a significant fall in mean pulmonary artery pressure and PVR. Kaplan-Meier survival estimates at one and two years were 98% and 91% respectively. The authors concluded that bosentan, with or without concomitant epoprostenol therapy, is safe and efficacious for the treatment of PAH in children.

## Dose of bosentan in treatment of PAH

The large placebo controlled study of two bosentan dosing regimens in adult patients with PAH (Rubin et al 2002) found that the dose of bosentan of 62.5 mg twice daily for 4-weeks followed by 125 mg twice daily was associated with equivalent efficacy as the higher dose of 250 mg twice daily with fewer side effects. Since that study, the dose of bosentan was 62.5 mg twice daily for 4-weeks followed by 125 mg twice daily, and this dosing regimen has been considered standard and hence been used in all future studies of adults with Bosentan in PAH. The dose of bosentan in children is dependent upon age and weight and has been described by Barst et al (2003) and Rosenzweig et al (2005).

Recommended dosing regimens for adults and children are summarized in Table 6.

## Safety and tolerability

The most significant adverse event in patients on bosentan treatment is the potential development of abnormal hepatic function and specifically a rise in hepatic amino transaminases. The basis of this is uncertain but it has been postulated that it is related to bosentan interfering with biliary salt excretion. The incidence of abnormal increase in hepatic amino transaminase levels to greater than three times normal varies from 9.7% in the largest placebo controlled study (although there was only a 4% incidence in the group receiving 125 mg twice daily of bosentan) (Rubin et al 2002) to as high as 14.9% in the longer observational studies (McLaughlin et al 2005).

Post marketing surveillance with Bosentan through the internet based (Trax) system has observed the use of bosentan in 4994 patients enrolled between May 2002 and November 2004. Median exposure over the two year observation period was approximately 35-weeks in patients with idiopathic PAH. The frequency of abnormal elevations in hepatic transaminase (ALT/AST) was approximately 8.4%. These elevations are reversible on stopping bosentan. Liver enzyme changes typically occur within the first six weeks of treatment initiation although it appears that they can occur at any time after the initiation of bosentan treatment.

As a result, liver amino transaminase levels must be measured prior to initiation of treatment and monthly thereafter. If elevated amino transaminase levels are seen, then changes in the monitoring and treatment of these patients are made according to a well defined protocol (Table 7). If liver amino transaminase elevations are accompanied by clinical symptoms of liver injury or an elevation in bilirubin greater than or equal to two times the upper limit of normal then treatment should be stopped.

**Table 6** Recommended dosing regimens for bosentan in adults and children

	Starting dose (1st 4-weeks)	Maintenance dose (Week 5 onwards)
Adults (>12 years of age)		
Bodyweight > 40 kg	62.5 mg twice daily	125 mg twice daily
Bodyweight < 40 kg	62.5 mg twice daily	62.5 mg twice daily
Children (<12 years of age)		
Bodyweight <10 kg	15.6 mg daily	15.6 mg twice daily
Bodyweight 10–20 kg	31.25 mg daily	31.25 mg twice daily
Bodyweight 20–40 kg	31.25 mg twice daily	62.5 mg twice daily
Bodyweight >40 kg	62.5 mg twice daily	125 mg twice daily

**Table 7** Monitoring and management of elevated liver enzymes for patients treated with bosentan

**Liver function monitored at least monthly (fortnightly after initiation or dose escalation), with dose modification (if required) based on following protocol:**

ALT/AST levels* <3 × ULN	Treatment and monitoring recommendations § Repeat Monitor fortnightly attend to potential other causes of elevation eg, concomitant medications, alcohol, biliary abnormalities
>3 and <5 × ULN	Repeat Reduce to starting dose or stop bosentan monitor ALT/AST at least fortnightly re-introduce at starting dose if pre-treatment levels are reached
>5 and <8 × ULN	Repeat Stop bosentan monitor ALT/AST at least fortnightly Re-introduce at starting dose if pre-treatment levels are reached
>8 × ULN	Repeat Stop permanently

**Note:**\*ALT, alanine transaminase; § Bosentan should be stopped if any elevation > 3 × ULN in AST/ALT levels occur in association with rise in bilirubin to > 2 × ULN and/or symptoms of liver dysfunction.

**Abbreviations:** AST, aspartate transaminase; ULN, Upper limit of normal

Bosentan treatment is associated with a fall in hemoglobin and hematocrit in up to 10% of patients. It is recommended that hemoglobin concentrations be checked after one and three months and every three months thereafter. The cause of this reduced hemoglobin with bosentan is unclear but in part may be related to dilutional effects as a result of fluid retention, in part as a result of the effects of ET<sub>B</sub> receptor blockade in the renal glomerulus.

Bosentan is teratogenic in rats and is contraindicated in pregnancy. It is not recommended to be used by lactating women. Other side effects such as headaches, flushing and syncope may occur due to the effects of bosentan on the systemic vasculature and associated systemic vasodilatation.

There is limited data on the safety of suddenly stopping bosentan. In an open labeled Australian study (Keogh et al 2007), 2% of patients died within 1-month of stopping bosentan. These were patients who were deteriorating despite therapy and it is unclear if their death reflected the natural history of the disease rather than due to bosentan withdrawal.

## Drug interactions

Bosentan is an inducer of the cytochrome P450 isoenzymes CYP2C9 and CYP3A4. Consequently, plasma concentrations of drugs metabolized by these isoenzymes will be decreased when bosentan is co-administered. Because estrogens and

progestogens are partially metabolized by these isoenzymes, there is a possibility of failure of contraception when bosentan is co-administered with oral contraceptive medication. The use of bosentan when co-administered with warfarin may be associated with reduced plasma concentrations of warfarin. In the large placebo controlled study (Rubin et al 2002) the frequency of changes in warfarin dose was similar amongst bosentan and placebo treated patients. However, personal experience suggests that the warfarin dose often needs to be increased when bosentan is co-administered. At the very least we would recommend intensified monitoring of international normalized ratio (INR) for patients on warfarin during bosentan initiation and up titration periods.

Co-administration of bosentan and cyclosporin or tacrolimus is contraindicated because of significant reduction in the effectiveness of these immunosuppressive agents. Likewise concomitant glibenclamide (glyburide in the United States) administration is contraindicated both because of an increased risk of elevated hepatic amino transaminase levels as well as a significant increase in glibenclamide concentration during concomitant use.

## Bosentan as part of combination therapy

The newer specific PAH therapies such as bosentan have resulted in significant improvements in exercise capacity, cardiopulmonary hemodynamics and survival. However, responses are variable and in many patients, disease progresses despite therapy. As a result an increasing number of patients are being considered for combination therapy (Hoepfer and Dinh-Xuan 2004).

Current therapies in the treatment of PAH act on the three intracellular pathways, endothelin, nitric oxide and prostacyclin, known to be abnormal in PAH (Figure 1). A logical extension therefore is to use a combination of two or more therapies each acting in synergy through a different pathway (Hoepfer and Dinh-Xuan 2004).

The combination of bosentan and sildenafil is of particular interest because both are oral agents, which are generally well tolerated. Hoepfer and colleagues (2004) reported the clinical course of 9 patients with severe idiopathic PAH, in whom bosentan caused transient clinical improvement, eventually followed by a decline in exercise tolerance, who then received adjunct treatment with sildenafil.

Bosentan was associated with an initial improvement in six minute walk test distance but this effect was not sustained. After an interval of 11 ± five months of bosentan treatment, sildenafil was added. Three months later, the six minute

walk test distance had increased by a mean of 115 m and this improvement persisted for a median follow up of nine months (Hoeper et al 2004).

In a small German study, involving eleven patients with different forms of pulmonary hypertension, but including idiopathic PAH and congenital heart disease, Lunze and co-authors (Lunze et al 2006) found that the combination of sildenafil and bosentan was associated with improvements in exercise capacity and reduction in mean pulmonary artery pressure. They found that the combination was well tolerated although one patient died suddenly for reasons that are not evident in the paper.

There is a pharmacological interaction between bosentan and sildenafil in that bosentan decreases the plasma concentration of sildenafil and sildenafil increases the plasma concentration of bosentan when they are co-prescribed in PAH (Paul et al 2005). However, this interaction does not appear to be associated with significant problems and the combination of bosentan and sildenafil does not appear to be associated with an increased risk of abnormal elevation of liver transaminases when compared to the use of bosentan alone (Hoeper, Kiely et al 2005).

Humbert and colleagues reported the results of a double blind placebo controlled prospective study in which 33 patients with PAH were commenced on intravenous epoprostenol treatment and were randomized to receive either bosentan or placebo. Hemodynamics, exercise capacity and functional class improved in both groups at week 16 and in the combination treatment group there was a trend for a greater (although non significant) improvement in all measured hemodynamic parameters. The authors concluded that this was an essentially negative study and that additional information was needed to evaluate the risk/benefit ratio of combined bosentan and epoprostenol therapy in PAH (Humbert, Barst et al 2004).

McLaughlin and colleagues (2006) reported the results of a randomized multi center double blind trial in 67 patients with PAH (55% idiopathic PAH, 45% associated PAH, 94% NYHA class III), in which inhaled iloprost (5 mcgm) or placebo was added to stable monotherapy with bosentan for 12-weeks. There was a treatment effect of adding iloprost of an increase in six minute walk distance of 26 m ( $p = 0.051$ ). The addition of iloprost was also associated with significant improvement in NYHA functional class and increased time to clinical worsening when compared with placebo. The authors concluded that within the limitations of the relatively small sample size, the addition of inhaled iloprost in patients with PAH with

reduced exercise capacity on bosentan monotherapy was both safe and efficacious.

## Goal oriented (combination) therapy

It has become increasingly clear that where it has been used, combination therapy with two or more agents has been associated with improvements in exercise capacity and functional class in patients with PAH. The question of which combination should be used and when remains unclear (Hoeper and Dinh-Xuan 2004).

Some authors have recommended adding increasing number of agents in combination, when specific treatment goals have not been met. Hoeper and colleagues have shown (Hoeper, Markevych et al 2005) that this goal oriented approach to therapy, based on achieving set functional criteria, has been associated with improved survival and less requirement for transplantation than in a historical cohort treated with monotherapy alone.

In summary, whilst ongoing studies are required in assessing bosentan as part of combination therapy it appears that such a strategy can be associated with improvements in exercise capacity, functional class and possibly survival in patients with PAH (Hoeper et al 2004; Hoeper and Dinh-Xuan 2004; Humbert, Barst et al 2004; Hoeper, Kiely et al 2005; Hoeper, Markevych et al 2005; Paul et al 2005; Lunze et al 2006; McLaughlin et al 2006).

## Atrial septostomy and lung transplantation

Atrial septostomy and lung transplantation are potential life-saving therapies, which are reserved for a small number of patients who are deemed likely to benefit from them and in whom the selective PAH therapies discussed above are ineffective. A detailed discussion of these therapies is beyond the scope of this article and the reader is referred elsewhere for a detailed discussion of surgical therapies in PAH including atrial septostomy and lung transplantation (ASTP et al 1998; Doyle et al 2004).

Sitbon and colleagues have described the criteria that they use to categorize patients as failing to respond to 3-months of intravenous epoprostenol therapy (Sitbon et al 2002). These patients were then considered for lung transplantation. Although no such criteria have been described for bosentan, alone or in combination with other agents, the reader is referred to the general principles prescribed by Sitbon and others when considering timing for referral for transplantation (ASTP et al 1998; Sitbon et al 2002; Doyle et al 2004).

## Cost-effectiveness and access to specific PAH therapies

There is limited data on the cost-effectiveness of bosentan or other specific PAH therapies (Wlodarczyk et al 2006), despite the importance that health authorities appropriately place on such data. These drugs are generally expensive and availability is limited in most countries. Almost all of the patients in the previously described clinical trials were in WHO (or NYHA) class III or IV at enrolment. This may reflect the resistance of some health authorities to subsidise therapy for patients in other functional classes.

It is our view that part of the responsibility of health care professionals is to advocate for reduced costs and greater availability of these therapies especially in developing countries.

## Summary

The dual endothelin receptor antagonist bosentan given at a dose (in adults) of 62.5 mg twice daily for four weeks followed by 125 mg twice daily is a safe and efficacious therapy in PAH. The use of bosentan as part of a comprehensive management plan has resulted in improvements in exercise capacity, functional class, quality of life and survival. Patients require regular monthly monitoring of liver function tests and clear guidelines are in place in terms of reducing or stopping bosentan therapy depending upon the results of these liver function tests. Because of bosentan's ability to induce the cytochrome p450 family, patients must be advised to contact their treating physician before initiation of other prescription medicines including oral contraceptives and antibiotics. Bosentan has been extensively used as monotherapy in PAH especially in patients with idiopathic PAH and scleroderma associated PAH but also appears to be efficacious in other forms of pulmonary hypertension including other connective tissue disease associated PAH, HIV associated PAH and Eisenmenger syndrome as well as in selected cases of chronic thromboembolic pulmonary hypertension. Bosentan may also have a role as part of combination therapy in patients who have responded sub optimally to monotherapy.

## References

- ASTP, ATS, ERS, ISHLT joint statement. 1998. International guidelines for the selection of lung transplant patients. *Am J Respir Crit Care Med*, 158:335–9.
- Barst RJ, Ivy D, Dingemans J, et al. 2003. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. *Clin Pharmacol Ther*, 73:372–82.
- Barst RJ, Rubin LJ, Long WA, et al. 1996. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. *N Engl J Med*, 334:296–302.
- Benedict NJ. 2007. Sitaxsentan in the management of pulmonary arterial hypertension. *Am J Health-System Pharmacy*, 64:363–8.
- Benigni A, Ramuzzi G. 1999. Endothelin antagonists. *Lancet*, 353:133–8.
- Black C. 2005. Pulmonary arterial hypertension: are we doing enough to identify systemic sclerosis patients at high risk of this rare condition? *Rheumatology (Oxford)*, 44:141–2.
- Bonderman D, Nowotny R, Skoro-Sajer N, et al. 2005. Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension. *Chest*, 128:2599–603.
- Bresser P, Fedullo PF, Auger WR, et al. 2004. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. *Eur Respir J*, 23:595–600.
- Channick RN, Simonneau G, Sitbon O, et al. 2001. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. *Lancet*, 358:1119–23.
- Clozel M, Gray GA, Breu V, et al. 1992. The endothelin ETB receptor mediates both vasodilation and vasoconstriction in vivo. *Biochem Biophys Res Commun*, 186:867–73.
- D'Alonzo GE, Barst RJ, Ayres SM, et al. 1991. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. *Ann Intern Med*, 115:343–9.
- Denton CP, Humbert M, Rubin L, et al. 2006. Bosentan therapy for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. *Ann Rheum Dis*, 65:1336–40.
- Doyle RL, McCrory D, Channick RN, et al. 2004. Journal of American College of Chest Physicians: Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. *Chest*, 126(1S):63S–71S.
- Farber HW, Loscalzo J. 2004. Pulmonary arterial hypertension. *N Engl J Med*, 351:1655–65.
- Filep JG, Fournier A, Foldes-Filep E. 1995. Acute pro-inflammatory actions of endothelin-1 in the guinea pig lung: Involvement of ETA and ETB receptors. *Br J Pharmacol*, 115:227–36.
- Fuster V, Steele PM, Edwards WD, et al. 1984. Primary pulmonary hypertension: natural history and the importance of thrombosis. *Circulation*, 70:580–7.
- Gabbay E, McNeil K, Williams TJ, et al. 2005. Bosentan for pulmonary arterial hypertension; the relationship between 6MWT and quality of life. *Am J Resp Crit Care Med*, 169:A175.
- Gaine SP, Rubin LJ. 1998. Primary pulmonary hypertension. *Lancet*, 352:719–25.
- Galie N. 2004. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. *Eur Heart J*, 25:2243–78.
- Galie N, Beghetti M, Gatzoulis MA, et al. 2006. Bosentan therapy in patients with Eisenmenger syndrome. *Circulation*, 114:48–54.
- Galie N, Ghofrani HA, Torbicki A, et al. 2005. Sildenafil citrate therapy for pulmonary arterial hypertension. *N Engl J Med*, 353:2148–57.
- Galie N, Grigioni F, Bacchi-Ruggianin K, et al. 1996. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension. *Eur J Clin Invest*, 26:273.
- Galie N, Hinderliter AL, Torbicki A, et al. 2003. Effects of the oral endothelin-receptor antagonist Bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. *J Am Coll Cardiol*, 41:1380–6.
- Galie N, Seeger W, Naeije R, et al. 2004. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. *J Am Coll Cardiol*, 43:81S–88S.
- Giaid A, Yanagisawa M, Langleben D, et al. 1993. Expression of Endothelin-1 in the lungs of patients with pulmonary hypertension. *N Engl J Med*, 328:1732–9.
- Girgis RE, Mathai SC, Krishnan JA, et al. 2005. Long-Term outcome of Bosentan treatment in idiopathic pulmonary arterial hypertension and pulmonary arterial hypertension associated with the scleroderma spectrum of diseases. *J Heart Lung Transplantation*, 24:1626–31.
- Hoepfer MM. 2002. Pulmonary hypertension in collagen vascular disease. *Eur Respir J*, 19:571–6.

- Hoeper MM, Dinh-Xuan AT. 2004. Combination therapy for pulmonary arterial hypertension: still more questions than answers. *Eur Respir J*, 24:339–40.
- Hoeper MM, Faulenbach C, Golpon H, et al. 2004. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. *Eur Respir J*, 24:1007–10.
- Hoeper MM, Kiely DG, Carlsen J, et al. 2005. Safety profile of pulmonary arterial hypertension patients treated with bosentan and sildenafil: results from the European surveillance program. *Am J Resp Crit Care Med*, 169:A135.
- Hoeper MM, Kramm T, Wilkens H, et al. 2005. Bosentan Therapy for Inoperable Chronic Thromboembolic Pulmonary Hypertension. *Chest*, 128:2363–7.
- Hoeper MM, Markevych I, Spierkerkoetter E, et al. 2005. Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. *Eur Respir J*, 26:858–63.
- Hughes R, George P, Parameshwar J, et al. 2005. Bosentan in inoperable chronic thromboembolic pulmonary hypertension. *Thorax*, 60:707.
- Hughes RJ, Jais X, Bonderman D, et al. 2006. Bosentan in inoperable chronic thromboembolic pulmonary hypertension: efficacy at 1 year. *Eur Respir J*, 28:138–43.
- Humbert M, Barst RJ, Robbins IM, et al. 2004. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. *Eur Respir J*, 24:353–9.
- Humbert M, Morrell NW, Archer SL, et al. 2004. Cellular and molecular pathobiology of pulmonary arterial hypertension. *J Am Coll Cardiol*, 43:13S–24S.
- Humbert M, Sitbon O, Simonneau G. 2004. Treatment of pulmonary arterial hypertension. *N Engl J Med*, 351:1425–36.
- Jais X, Ghofrani A, Hoeper MM, et al. 2007. Bosentan for inoperable chronic thromboembolic pulmonary hypertension (CTEPH): a randomized, placebo-controlled trial. *Am J Resp Crit Care Med*, 173:A896.
- Jamieson SW, Kapelanski DP, Sakakibara N, et al. 2003. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. *Ann Thorac Surg*, 76:1457–64.
- Jones K, Higenbottam T, Wallwork J. 1989. Pulmonary vasodilation with prostacyclin in primary and secondary pulmonary hypertension. *Chest*, 96:784–9.
- Katwa LC, Guarda E, Weber KT. 1993. Endothelin receptors in cultured adult rat cardiac fibroblasts. *Cardiovasc Res*, 27:2125–9.
- Keogh AM, McNeil KD, Wlodarczyk J, et al. 2007. Quality of life in pulmonary arterial hypertension: improved and maintained with bosentan. *J Heart Lung Transplantation*, 26:181–7.
- Kotlyar E, Sy R, Keogh AM. 2006. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital cardiac disease. *Cardiol Young*, 16:268–74.
- Lane KB, Machado RD, Pauciulo MW, et al. 2000. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. *Nat Genet*, 26:81–4.
- Levin ER. 1995. Endothelins. *N Engl J Med*, 333:356–63.
- Lunze K, Gilbert N, Mebus S, et al. 2006. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. *Eur J Clin Invest*, 36 S3:32–8.
- McLaughlin VV, Oudiz RJ, Frost A, et al. 2006. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. *Am J Respir Crit Care Med*, 174:1257–63.
- McLaughlin VV, Sitbon O, Badesch DB, et al. 2005. Survival with first-line bosentan in patients with primary pulmonary hypertension. *Eur Respir J*, 25:244–9.
- Moser KM, Auger WR, Fedullo PF. 1990. Chronic major-vessel thromboembolic pulmonary hypertension. *Circulation*, 81:1735–43.
- Musk M, Chambers D, Lawrence S, et al. 2006. Bosentan improves WHO functional class, exercise capacity and RV size in inoperable chronic thromboembolic pulmonary hypertension (CTEPH). *J Heart Lung Transplantation*, 25:S77.
- Newman JH, Wheller L, Lane KB, et al. 2001. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. *N Engl J Med*, 345:319–24.
- Neylon CB, Avdonin PV, Dilley RJ, et al. 1994. Different electrical responses to vasoactive agonists in morphologically distinct smooth muscle cell types. *Circ Res*, 75:733–41.
- Olschewski H, Simonneau G, Galie N, et al. 2002. Aerosolized Iloprost Randomized Study Group: Inhaled iloprost for severe pulmonary hypertension. *N Engl J Med*, 347:322–9.
- Paul GA, Gibbs SR, Boobis AR, et al. 2005. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. *Br J Clin Pharmacol*, 60:107–12.
- Provencher S, Sitbon O, Humbert M, et al. 2006. Long-term outcome with first line bosentan therapy in idiopathic pulmonary arterial hypertension. *Eur Heart J*, 27:589–95.
- Rich S, Kaufmann E, Levy PS. 1992. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. *N Engl J Med*, 327:76–81.
- Rosenzweig EB, Ivy DD, Wilditz A, et al. 2005. Effects of long-term bosentan in children with pulmonary arterial hypertension. *J Am Coll Cardiol*, 46:697–704.
- Rubin LJ. 2004. ACCP evidence-based clinical practice guidelines: Diagnosis and management of pulmonary arterial hypertension. *Chest*, 126:1S–92S.
- Rubin LJ, Badesch DB, Barst RJ, et al. 2002. Bosentan therapy for pulmonary arterial hypertension. *N Engl J Med*, 346:896–903.
- Rubin LJ, Hoeper MM, Klepetko W, et al. 2006. Current and future management of chronic thromboembolic pulmonary hypertension: from diagnosis to treatment responses. *Proc Am Thorac Soc*, 3:601–7.
- Runo JR, Loyd JE. 2003. Primary pulmonary hypertension. *Lancet*, 361:1533–44.
- Simonneau G, Barst RJ, Galie N, et al. 2002. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. *Am J Respir Crit Care Med*, 165:800–4.
- Simonneau G, Galie N, Rubin LJ, et al. 2004. Clinical classification of pulmonary hypertension. *J Am Coll Cardiol*, 43:5S–12S.
- Sitbon O, Badesch DB, Channick RN, et al. 2003. Effects of the dual endothelin receptor antagonist Bosentan in patients with pulmonary arterial hypertension: A 1-year follow-up study. *Chest*, 124:247–54.
- Sitbon O, Gressin V, Speich R, et al. 2004. Bosentan in pulmonary arterial hypertension associated with HIV infection. *Am J Respir Crit Care Med*, 170:1212–17.
- Sitbon O, Humbert M, Nunes H, et al. 2002. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. *J Am Coll Cardiol*, 40:780–8.
- Sitbon O, McLaughlin VV, Badesch DB, et al. 2005. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first-line oral bosentan compared with an historical cohort of patients started on iv epoprostenol. *Thorax*, 60:1025–30.
- Steiner MK, Preston IR, Klinger JR, et al. 2006. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study. *Chest*, 130:1471–80.
- Stewart S, Murphy NF, McMurray JJV, et al. 2007. A population-based analysis of pulmonary arterial hypertension in Scotland (1996–2001). *Eur Respir J*, (in press).
- Strange C. 2005. Treatment for Secondary Pulmonary Hypertension. *Chest*, 128:1897–8.
- Voelkel NF, Tuder RM, Weir EK. 1997. Pathophysiology of primary pulmonary hypertension: From physiology to molecular mechanisms. In: Rubin L, Rich S eds. Primary Pulmonary Hypertension, New York, NY: Marcel Dekkerp 83–129.
- Williams MH, Das C, Handler CE, et al. 2006. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. *Heart*, 92:926–32.
- Wlodarczyk JH, Cleland LG, Keogh AM, et al. 2006. Public funding of Bosentan for the treatment of pulmonary arterial hypertension in Australia. *Pharmacoeconomics*, 24:903–15.
- Zapol WM, Falke KJ, Hurford WE, et al. 1994. Inhaling nitric oxide: a selective pulmonary vasodilator and bronchodilator. *Chest*, 105:87S–91S.